Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1994-07-21
1996-10-08
Budens, Robert D.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
4241301, 4241411, 514 44, B61K 39395
Patent
active
055629040
ABSTRACT:
Methods and compositions are provided for facilitating gene therapy procedures involving the transduction of target cells with retroviral vector particles in the presence of complement containing body fluids. The administration of soluble complement inhibitor molecules to body fluids prevents the complement mediated inactivation of the retroviral vector particles, and provides a safety mechanism for such gene therapy procedures, as the action of soluble complement inhibitors is transient, and any retroviral vector particles present after the return of uninhibited complement activity will be inactivated. Preferred soluble complement inhibitors for use in the practice of the present invention include complement inhibitory anti-complement component mAbs (including complement inhibitory anti C5 antibodies).
REFERENCES:
Anderson, W. F., Human Gene Therapy 5:281-282, 1994.
Liszewski et al., "The Complement System," in Fundamental Immunology3rd Ed., Paul, W. E., Ed. Raven Press, New York, 1993.
Takeuchi et al., J. Virology 68(12):8001-8007, Dec. 1994.
Albrecht et al., "Herpesvirus saimiri has a gene specifying a homologue of the cellular membrane glycoprotein CD59" Virology, 190:527-530, 1992.
Albrecht and Fleckenstein, "New member of the multigene family of complement control proteins in Herpesvirus saimiri" J Virology, 66:3937-3940, 1992.
Bartholomew et al., "Lysis of oncornaviruses by human serum" J Exp Med, 147:844-853, 1978.
Bartholomew and Esser, "Mechanism of antibody-independent activation of the first component of complement (C1) on retrovirus membranes" Biochem, 19:2847-2853, 1980.
Cooper et al., "Lysis of RNA tumor viruses by human serum: Direct antibody-independent triggering of the classical complement pathway" J Exp Med, 144:970-984, 1976.
Culver et al., "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors" Science, 256:1550-1552, 1992.
Galili et al., "Evolutionary relationship between the natural anti-Gal antibody and the Gal.alpha.1.fwdarw.3 Gal epitope in primates" Proc Natl Acad Sci, USA, 84:1369-1373, 1987.
Isaacs et al., "Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence" Proc Natl Acad Sci, USA, 89:628-632, 1992.
McNearney et al., "Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity" J Exp Med, 166:1525-1535, 1987.
Neethling et al., "Protection of pig kidney (PK15) cells from the cytotoxic effect of anti-pig antibodies by .alpha.-galactosyl oligosaccharides" Transplantation, 57:959-963, 1994.
Ram et al., "Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors" J Neurosurg, 79:400-407, 1993.
Repik et al., "Differential host-dependent expression of .alpha.-galactosyl epitopes on viral glycoproteins: a study of eastern equine encephalitis virus as a model" J Gen Virol, 75:1177-1181, 1994.
Rother et al., "Inhibition of complement-mediated cytolysis by the terminal complement inhibitor of herpesvirus saimiri" J Virol, 68:730-737, 1994.
Welsh et al., "Human serum lyses RNA tumour viruses" Nature, 257:612-614, 1975.
Welsh et al., "Inactivation and lysis of oncornaviruses by human serum" Virology, 74:432-440, 1976.
Widner and Brundin, "Immunological aspects of grafting in the mammalian central nervous system. A review and speculative synthesis", Brain Res Rev, 13:287-324, 1988.
Immunology, vol. 76, 1992, Rooney et al., "Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid" pp. 541-547.
The Journal Of Immunology, vol. 151, 1993, Lehto et al., "Interactions of soluble CD59 with the terminal complement complexes" pp. 4941-4949.
Mason James M.
Rollins Scott A.
Rother Russell P.
Squinto Stephen P.
Alexion Pharmaceuticals, Inc.
Budens Robert D.
Fidel, Ph.D. Seth A.
Klee, Ph.D. Maurice M.
LandOfFree
Retroviral transduction of cells using soluble complement inhibi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Retroviral transduction of cells using soluble complement inhibi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Retroviral transduction of cells using soluble complement inhibi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-55436